Randomized controlled trial comparing superovulation with letrozole versus recombinant follicle-stimulating hormone combined with intrauterine insemination for couples with unexplained infertility who had failed clomiphene citrate stimulation and intrauterine insemination

被引：32

作者：

Gregoriou, Odysseas ^{[1
]}

Vlahos, Nikos F. ^{[1
,2
]}

Konidaris, Socrates ^{[1
]}

Papadias, Konstantinos ^{[1
]}

Botsis, Dimitrios ^{[1
]}

Creatsas, George K. ^{[1
]}

机构：

[1] Aretaie Univ Hosp, Athens 11528, Greece

[2] Johns Hopkins Univ Hosp, Med Ctr, Lutherville Timonium, MD USA

来源：

FERTILITY AND STERILITY | 2008年 / 90卷 / 03期

关键词：

letrozole; IUI; gonadotropins; unexplained infertility; aromatase inhibitors;

D O I：

10.1016/j.fertnstert.2007.06.099

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Objective: To compare the efficacy of letrozole to recombinant FSH for ovarian stimulation combined with IUI in a group of patients that had failed to conceive after clomiphene citrate (CC) and IUI. Design: Prospective randomized trial with human subjects. Setting: University-based fertility center. Patient(s): Fifty couples with unexplained infertility that failed to conceive after three cycles of CC combined to IUI. Intervention(s): Couples were randomized to undergo superovulation either with letrozole or with recombinant FSH combined to IUI. Main Outcome Measure(s): Clinical pregnancy per cycle of treatment and clinical pregnancy per couple. Result(s): Pregnancy rate (PR) per cycle was 8.9% in the letrozole group as compared with 14% in the gonadotropin IUI group. This resulted in a cumulative PR per couple of 24% versus 36% and a take home baby rate of 20% versus 28%. Endometrial thickness was significantly lower in the letrozole group (7.1 +/- 2.3 vs 8.6 +/- 1.8). Conclusion(s): Ovarian stimulation with letrozole is associated with acceptable PRs compared with gonadotropin with significant less cost, risks, and patient inconvenience.

引用

页码：678 / 683

页数：6

共 41 条

[1] EXOGENOUS ESTROGEN THERAPY CONCURRENT WITH CLOMIPHENE CITRATE - LACK OF EFFECT ON SERUM SEX-HORMONE LEVELS AND ENDOMETRIAL THICKNESS [J].